Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2012

Study Completion Date

March 31, 2014

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Velcade and Vorinostat

Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.

Trial Locations (1)

22908

University of Virginia, Charlottesville

All Listed Sponsors
lead

University of Virginia

OTHER

NCT00731952 - Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter